Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2011

01-03-2011 | Original Article

Computer-Assisted Analysis of Abrasive Transepithelial Brush Biopsies Increases the Effectiveness of Esophageal Screening: A Multicenter Prospective Clinical Trial by the EndoCDx Collaborative Group

Authors: J. F. Johanson, J. Frakes, D. Eisen, EndoCDx Collaborative Group

Published in: Digestive Diseases and Sciences | Issue 3/2011

Login to get access

Abstract

Background

The sensitivity of screening for Barrett’s esophagus (BE) and esophageal dysplasia (ED) is hampered by the limited amount of tissue that can be sampled by forceps biopsy (FB).

Aim

The aim of this study was to evaluate computer assisted analysis of an abrasive, transepithelail brush biopsy as an adjunct to FB to increase detection of BE and ED.

Methods

This was a multicenter prospective trial of patients being screened for BE and ED. Each patient had two brush biopsies (BB) and then random four-quadrant FB every 1–2 cm of the esophagus. All BB were examined with computer assistance by pathologists at CDx Laboratories (Suffern, NY), and all FB were examined by the investigators’ local pathologists.

Results

Of 1,266 patients enrolled, 363 were diagnosed with BE by FB alone and 146 additional cases of BE were identified by adding BB. The addition of BB to FB increased the overall detection of BE by 39.8% (95% CI 32–48%). This added detection of BE in 11.5% of all patients tested with the BB (146/1266) resulted in a number of patients needed to test (NNT) to obtain each additional positive finding of Barrett’s esophagus of 8.7. Among a subset of 848 patients with gastroesophageal reflux disease and no prior history of BE, the addition of BB to FB identified an additional 105 patients with BE increasing the overall detection of BE by 70.5% (95% CI 54–90%). Dysplasia was diagnosed in 16 patients by FB alone, with an additional 14 cases detected by adding BB. The addition of BB to FB thus increased the detection of ED by 87.5%.

Conclusion

These results suggest that adjunctive computer-assisted analysis of an abrasive brush biopsy has the potential to substantially improve the detection of Barrett’s esophagus and dysplasia in screening populations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mashimo H, Wagh MS, Goyal RK. Surveillance and screening for Barrett esophagus and adenocarcinoma. J Clin Gastroenterol. 2005;39:S33–S41.CrossRefPubMed Mashimo H, Wagh MS, Goyal RK. Surveillance and screening for Barrett esophagus and adenocarcinoma. J Clin Gastroenterol. 2005;39:S33–S41.CrossRefPubMed
2.
go back to reference Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54:i1–i5.CrossRefPubMed Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54:i1–i5.CrossRefPubMed
3.
go back to reference Cossentino MJ, Wong RK. Barrett’s esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:128–135.PubMed Cossentino MJ, Wong RK. Barrett’s esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:128–135.PubMed
5.
go back to reference Shaheen NJ. Advances in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2005;128:1554–1566.CrossRefPubMed Shaheen NJ. Advances in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2005;128:1554–1566.CrossRefPubMed
6.
go back to reference Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601.CrossRefPubMed Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601.CrossRefPubMed
7.
go back to reference Sampliner RE. Epidemiology, pathophysiology, and treatment of Barrett’s esophagus: reducing mortality from esophageal adenocarcinoma. Med Clin North Am. 2005;89:293–312.CrossRefPubMed Sampliner RE. Epidemiology, pathophysiology, and treatment of Barrett’s esophagus: reducing mortality from esophageal adenocarcinoma. Med Clin North Am. 2005;89:293–312.CrossRefPubMed
8.
go back to reference Olliver JR, et al. Risk factors, DNA damage, and disease progression in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:620–625.CrossRefPubMed Olliver JR, et al. Risk factors, DNA damage, and disease progression in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:620–625.CrossRefPubMed
9.
go back to reference Kyrgidis A, et al. New molecular concepts of Barrett’s esophagus: clinical implications and biomarkers. J Surg Res. 2005;125:189–212.CrossRefPubMed Kyrgidis A, et al. New molecular concepts of Barrett’s esophagus: clinical implications and biomarkers. J Surg Res. 2005;125:189–212.CrossRefPubMed
10.
go back to reference Reid BJ, et al. Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102:1212–1219.PubMed Reid BJ, et al. Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102:1212–1219.PubMed
11.
go back to reference Waye JD. Upper gastrointestinal endoscopy. Mt Sinai J Med. 1995;62:50–59.PubMed Waye JD. Upper gastrointestinal endoscopy. Mt Sinai J Med. 1995;62:50–59.PubMed
12.
go back to reference Sharma P. Review article: emerging techniques for screening and surveillance in Barrett’s oesophagus. Aliment Pharmacol Ther. 2004;20:63–70; discussion 95–96.CrossRefPubMed Sharma P. Review article: emerging techniques for screening and surveillance in Barrett’s oesophagus. Aliment Pharmacol Ther. 2004;20:63–70; discussion 95–96.CrossRefPubMed
13.
14.
go back to reference Falk GW, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176.CrossRefPubMed Falk GW, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176.CrossRefPubMed
15.
go back to reference Bergman JJ, Tytgat GN. New developments in the endoscopic surveillance of Barrett’s oesophagus. Gut. 2005;54:i38–i42.CrossRefPubMed Bergman JJ, Tytgat GN. New developments in the endoscopic surveillance of Barrett’s oesophagus. Gut. 2005;54:i38–i42.CrossRefPubMed
16.
go back to reference Bergman JJ. Diagnosis and therapy of early neoplasia in Barrett’s esophagus. Curr Opin Gastroenterol. 2005;21:466–471.PubMed Bergman JJ. Diagnosis and therapy of early neoplasia in Barrett’s esophagus. Curr Opin Gastroenterol. 2005;21:466–471.PubMed
18.
go back to reference Kara MA, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37:929–936.CrossRefPubMed Kara MA, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37:929–936.CrossRefPubMed
19.
go back to reference Egger K, et al. Biopsy surveillance is still necessary in patients with Barrett’s oesophagus despite new endoscopic imaging techniques. Gut. 2003;52:18–23.CrossRefPubMed Egger K, et al. Biopsy surveillance is still necessary in patients with Barrett’s oesophagus despite new endoscopic imaging techniques. Gut. 2003;52:18–23.CrossRefPubMed
20.
go back to reference Boyce HW. Barrett esophagus: endoscopic findings and what to biopsy. J Clin Gastroenterol. 2003;36:S6–S18; discussion S26–S28.CrossRefPubMed Boyce HW. Barrett esophagus: endoscopic findings and what to biopsy. J Clin Gastroenterol. 2003;36:S6–S18; discussion S26–S28.CrossRefPubMed
21.
go back to reference Wong Kee Song LM. Optical spectroscopy for the detection of dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol. 2005;3:S2–S7.CrossRefPubMed Wong Kee Song LM. Optical spectroscopy for the detection of dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol. 2005;3:S2–S7.CrossRefPubMed
22.
go back to reference Sciubba JJ. Improving detection of precancerous and cancerous oral lesions. Computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc. 1999;130:1445–1457.PubMed Sciubba JJ. Improving detection of precancerous and cancerous oral lesions. Computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc. 1999;130:1445–1457.PubMed
23.
go back to reference Scheifele C, et al. The sensitivity and specificity of the OralCDx technique: evaluation of 103 cases. Oral Oncol. 2004;40:824–828.CrossRefPubMed Scheifele C, et al. The sensitivity and specificity of the OralCDx technique: evaluation of 103 cases. Oral Oncol. 2004;40:824–828.CrossRefPubMed
Metadata
Title
Computer-Assisted Analysis of Abrasive Transepithelial Brush Biopsies Increases the Effectiveness of Esophageal Screening: A Multicenter Prospective Clinical Trial by the EndoCDx Collaborative Group
Authors
J. F. Johanson
J. Frakes
D. Eisen
EndoCDx Collaborative Group
Publication date
01-03-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1497-6

Other articles of this Issue 3/2011

Digestive Diseases and Sciences 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.